Press Releases

Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that data from a clinical study of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis were presented during the...

Board to Initiate CEO Search Process; Scott Hirsch Appointed as Interim CEO MALVERN, Pa., Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty...

Raises 2024 Financial Expectations Provides 2025 Financial Expectations MALVERN, Pa., Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI), a diversified specialty...

Two presentations include data from a Phase 2 study of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis Endo is currently enrolling patients in a Phase 3 study A...

Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it will release its second quarter 2024 financial results on August 27, 2024, prior to market open. Members of Endo's senior...